Cellumen, Inc. is the Cellular Systems Biology Company. Cellumen focuses on the cell as an integrated and interacting network of genes, proteins and metabolites responsible for normal and abnormal (disease) function. To promote efficient drug discovery and development, the company offers solutions to the dual challenges of efficacy and toxicity. The company’s products and services have application in each of the major segments of the pharmaceutical pipeline: drug discovery (“cellular models of disease”), drug development (“cytotoxicity profiling”) and clinical trials (“patient sample profiling”). The Cellumen team leverages its experience and expertise in High Content Screening, cell-based assays, advanced reagents and bioinformatics to create high value solutions.
Cellumen uses cells and surrogate systems to optimize the drug discovery process. The company’s functional biology approach puts a variety of bio-sensors and cell manipulation reagents in different types of cells, and examines their response to drugs and biologics. This measures efficacy and potential toxicity well before entering expensive clinical testing. In addition, it is also projected to improve clinical trial enrollment and increase new drug efficacy by conducting theranostic patient profiles.
Website:
www.cellumen.com
Safeguard Partner Company since 2007
